Overview
Epitalon (Ala-Glu-Asp-Gly) is a tetrapeptide derived from work by Vladimir Khavinson and colleagues at the St. Petersburg Institute of Bioregulation and Gerontology. It was synthesised as a short-peptide mimic of epithalamin, a pineal-gland extract studied in the Soviet Union for age-related neuroendocrine changes.
The published literature on Epitalon is concentrated in Russian-language journals and a small number of translated reviews. The core claim across this body of work is that the peptide influences pineal function, melatonin secretion patterns and — most provocatively — telomerase activity in somatic cells.
Outside the Khavinson group, independent replication has been limited. The molecule remains an interesting research tool with a particular relevance to chronobiology and ageing research, but its evidence base is narrower than its popular reputation suggests.
Mechanism of Action
The most-cited mechanistic finding is up-regulation of telomerase reverse transcriptase (TERT) expression and activity in cultured human fibroblasts, leading to telomere elongation over multiple passages. This work has been replicated within the originating laboratory but rarely outside it.
A second strand of research describes effects on pineal melatonin biosynthesis and on the timing of melatonin secretion, particularly in aged rodent models where the circadian amplitude is blunted.
Proposed downstream effects on antioxidant gene expression and on the hypothalamic-pituitary axis have also been reported, though the mechanistic chain from receptor binding to gene expression is not fully mapped.
Research Summary
- Epithalon peptide induced telomerase activity and telomere elongation in cultured human somatic cells. [1]
- Combined melatonin/epithalamin treatment reduced markers of oxidative stress in aged rat brain tissue under hypoxic challenge. [2]
- Reviews of peptide-bioregulator research report improved survival metrics in some aged-rodent studies, though independent replication outside the originating research group is limited. [3]
What we don't know yet
- Pharmacokinetics in humans are essentially unpublished in the international literature.
- Whether systemic administration recapitulates the in-vitro telomerase effects in vivo is unresolved.
- Long-term oncologic safety of telomerase up-regulation has not been characterised in humans.
Protocol Considerations
Research framing only. The Protides Research Library does not provide dosing guidance for human use. The figures below summarise published research-protocol ranges and storage conditions; they are not clinical recommendations.
Stack Interactions
Storage & Handling
- Lyophilised
- −20 °C, desiccated. Stable ≥ 24 months.
- Reconstituted
- 2–8 °C in sterile water. Use within 14 days.
- Shelf life
- Lyophilised ≥ 24 months at −20 °C. Reconstituted ~14 d at 2–8 °C.
FAQ
Is the telomerase claim well established?
It is well documented within the originating laboratory; independent replication in human cells is limited.
Does it cross the blood-brain barrier?
Functional CNS effects are reported in animal data, but direct evidence of intact passage is sparse.
Is Epitalon approved as a drug anywhere?
It is registered as a peptide bioregulator in Russia, but not approved as a therapeutic by FDA, EMA, or comparable regulators.
How does it compare to NAD+ for longevity research?
They operate in different pathways: Epitalon targets telomere maintenance and pineal function; NAD+ targets cellular energy and sirtuin activity.
What is the typical research protocol?
Short cycles of daily injection, often in courses of 10–20 days, derived from the Khavinson protocols.
Is telomerase activation safe?
Long-term oncologic safety is an open question. Telomerase is up-regulated in most cancers.
References
- [1]Epithalon peptide induces telomerase activity and telomere elongation in human somatic cellsBull. Exp. Biol. Med., 2003
- [2]
- [3]Peptide bioregulation of aging: results and prospectsBiogerontology, 2010
